SAB Biotherapeutics, Inc.SABSNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank67
5Y CAGR-2.6%
Year-over-Year Change
Year-over-year SG&A expense growth
5Y CAGR
-2.6%/yr
Long-term compound
Percentile
P67
Within normal range
vs 5Y Ago
0.9x
Contraction
Streak
1 yr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| 2025 | 57.42% |
| 2024 | -61.03% |
| 2023 | 45.27% |
| 2022 | -4.11% |
| 2021 | 152.30% |
| 2020 | 65.33% |
| 2019 | 0.00% |